• Radiation Oncology Journal
• /
• 제36권4호
• /
• pp.295-303
• /
• 2018

Purpose: We evaluated prognostic value of the 8th edition of the American Joint Committee on Cancer/International Union for Cancer Control (AJCC/UICC) staging system for nasopharyngeal cancer and investigated whether tumor volume/metabolic information refined prognostication of anatomy based staging system. Materials and Methods: One hundred thirty-three patients with nasopharyngeal cancer who were staged with magnetic resonance imaging (MRI) and treated with intensity-modulated radiotherapy (IMRT) between 2004 and 2013 were reviewed. Multivariate analyses were performed to evaluate prognostic value of the 8th edition of the AJCC/UICC staging system and other factors including gross tumor volume and maximum standardized uptake value of primary tumor (GTV-T and SUV-T). Results: Median follow-up period was 63 months. In multivariate analysis for overall survival (OS), stage group (stage I-II vs. III-IVA) was the only significant prognostic factor. However, 5-year OS rates were not significantly different between stage I and II (100% vs. 96.2%), and between stage III and IVA (80.1% vs. 71.7%). Although SUV-T and GTV-T were not significant prognostic factors in multivariate analysis, those improved prognostication of stage group. The 5-year OS rates were significantly different between stage I-II, III-IV (SUV-T ≤ 16), and III-IV (SUV-T > 16) (97.2% vs. 78% vs. 53.8%), and between stage I, II-IV (GTV-T ≤ 33 mL), and II-IV (GTV-T > 33 mL) (100% vs. 87.3% vs. 66.7%). Conclusion: Current anatomy based staging system has limitations on prognostication for nasopharyngeal cancer despite the most accurate assessment of tumor extent by MRI. Tumor volume/metabolic information seem to improve prognostication of current anatomy based staging system, and further studies are needed to confirm its clinical significance.

• 대한두경부종양학회지
• /
• 제38권2호
• /
• pp.7-13
• /
• 2022

Human papillomavirus (HPV) is a causative agent for a subset of oropharyngeal cancer (OPC). The current standard of care (SOC) for locally advanced OPC is 70 Gy definitive radiotherapy (RT) concurrent with cisplatin, which entails significant proportions of acute and late grade 3 or higher toxicities. Accordingly, discovery of favorable prognosis of HPV-related OPC has led to enthusiasm to attenuate subspecialties therapy in multidisciplinary treatment. Diverse deintensification strategies were investigated in multiple phase 2 trials with an assumption that attenuated treatments result in comparable oncologic outcome and less toxicities compared with SOC. Several trials on chemotherapy deintensification revealed that concomitant administration of cisplatin is not to be omitted or substituted for cetuximab without compromising progression-free survival or local control. A transoral robotic surgery (TORS) is investigated as alternative local treatment, but TORS plus SOC or mild deintensified adjuvant RT showed similar toxicities and inferior oncologic outcomes compared with SOC definitive RT or moderately deintensified RT. However, it has been reported that TORS plus deintensified 30-36 Gy adjuvant RT results in excellent outcome and less late toxicity compared with SOC adjuvant RT. Several phase 2 trials reported apparently equivalent progression-free survival and local control and similar adverse effects with moderately deintensified 60 Gy RT compared with SOC 70 Gy RT. Further dose reduction below 60 Gy has been investigated using biology-directed approaches, which use response to induction chemotherapy or metabolic images to triage HPV-positive OPC for deintensified RT. In summary, these trials provide valuable insights for future directions. Available evidence consistently showed that moderately deintensified RT is effective and safe for HPV-positive OPC in both definitive and adjuvant settings. Concurrent cisplatin remains an essential component without which progression-free survival is significantly compromised for advanced HPV-positive OPC. A simple incorporation of TORS to SOC may be detrimental for oncologic outcome without anticipated toxicity reduction. Given the lack of level 1 evidence, it is prudent to curb an unjustified deviation from the current SOC and limit any deintensified strategies to clinical trials and adhere to the current SOC.

• Radiation Oncology Journal
• /
• 제30권3호
• /
• pp.132-139
• /
• 2012

Purpose: The purpose of this prospective multi-institutional study was to evaluate the nutritional status of patients undergoing radiotherapy (RT) for treatment of head and neck, lung, or gastrointestinal cancer. Materials and Methods: A total of 1,000 patients were enrolled in this study at seven different hospitals in Seoul, Korea between October 2009 and May 2010. The nutritional status of patients after receiving 3 weeks of RT was evaluated using subjective global assessment (SGA). The nutritional status of each patient was rated as well nourished (A), moderately malnourished (B), or severely malnourished (C). Results: The mean age of patients in this study was $59.4{\pm}11.9$ years, and the male to female ratio was 7:3. According to the SGA results, 60.8%, 34.5%, and 4.7% of patients were classified as A, B, or C, respectively. The following criteria were significantly associated with malnutrition (SGA B or C; p < 0.001): loss of subcutaneous fat or muscle wasting (odds ratio [OR], 11.473); increased metabolic demand/stress (OR, 8.688); ankle, sacral edema, or ascites (OR, 3.234); and weight loss ${\geq}5%$ (OR, 2.299). Conclusion: SGA was applied successfully to assess the nutritional status of most patients. The prevalence of malnutrition in a radiation oncology department was 39.2%. The results of this study serve as a basis for implementation of nutrition intervention to patients being treated at radiation oncology departments.

• Nuclear Engineering and Technology
• /
• 제42권5호
• /
• pp.600-607
• /
• 2010

Rhenium-186, having a half-life of 90.64 h, is an important radionuclide, used in metabolic radiotherapy and radio immunotherapy. $^{186}Re$ hydroxyethylidene diphosphonate (HEDP) is a new compound used for the palliation of painful skeletal metastases. Its production is achieved via charged-particle-induced reactions; the data are available in EXFOR library. For the work discussed in this paper, production of $^{186}Re$ was done via $^{nat}W(p,n)^{186}Re$ nuclear reaction. Pellets of $^{nat}W$ were used as targets and were irradiated with 15, 17.5, 20, 22.5, 25 MeV proton beams at 5 ${\mu}A$ current. The radiochemical separation was performed by the ion exchange chromatography method. The production yield achieved at 25 MeV was 1.91 $MBq{\cdot}{\mu}A^{-1}{\cdot}h^{-1}$. Excitation functions for the $^{186}Re$ radionuclide, via $^{186}W(p,n)^{186}Re$ and $^{186}W(d,2n)^{186}Re$ reactions were calculated by ALICE-ASH and TALYS-1.0 codes to validate and fit the experimental data and to obtain a recommended set of data for $^{186}W(p,n)^{186}Re$ reaction. Required thickness of the targets was obtained by SRIM code for each reaction.

• 대한한방내과학회지
• /
• 제43권4호
• /
• pp.751-760
• /
• 2022

Objective: To show a decrease in tumor recurrence and improvement in quality of life in patients with recurrent cervical cancer. Method: A 58-year-old female patient diagnosed with recurrent cervical cancer in February 2021 was treated for 14 months with integrative cancer treatment (ICT) to decrease the tumor size and improve chemotherapy-induced peripheral neuropathy (CIPN) and nausea. The patient underwent chemotherapy or concomitant chemoradiation therapy (CCRT) with ICT. Radiologic outcomes were assessed by abdomen & pelvis computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET-CT) based on the Response Evaluation Criteria in Solid Tumors (RECIST) protocol. Clinical outcomes were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), Eastern Cooperative Oncology Group (ECOG), and a numeric rating scale (NRS). Result: During the 14 months of treatment, the size and metabolic activity of the recurrent tumor decreased and underwent partial remission based on RECIST. The NRS scores for CIPN and nausea were improved, and the ECOG score improved from grade 2 to 1. No serious side effects of grade 3 or higher were noted on the NCI-CTCAE test. Conclusion: This case suggests that ICT may have a synergetic effect with chemotherapy or radiotherapy for recurrent cervical cancer.

• Radiation Oncology Journal
• /
• 제22권2호
• /
• pp.98-105
• /
• 2004

목적 : 두경부종양에서 근치적 목적의 방사선치료를 시행하는 경우 종양의 방사선 반응도를 예측하는 것은 방사선치료 계획을 세우는 데 있어서 매우 중요하다. 따라서 본 저자들은 방사선치료 46 Gy 시점과 종료 시점에서 FDG-PET을 시행하여 방사선치료 반응성을 예측할 수 있는지 알아보고자 하였다. 대상 및 방법 : 2002년 10월부터 2003년 5월까지 서울아산병원 방사선종양학과에서 두경부종양으로 진단 받고 근치적 목적의 방사선치료를 시행 받은 22명에 대한 전향적 분석을 시행하였다. 본 연구계획서는 본원 임상윤리위원회를 통과하였고, 자발적으로 참여한 환자들에서 서면으로 동의를 받고 연구대상에 포함하였다. 모든 환자는 1차 FDG-PET을 방사선치료 시작 4주 이내에 시행하고 방사선치료 45 Gy 시점에서 제 2차 FDG-PET을 촬영하였고, 처음 계획된 선량이 모두 조사되는 시점에서 제 3차 FDG-PET을 시행하였다. 모든 환자는 최소한 방사선치료 종료 후 3개월 이상 추적하여 방사선치료 반응을 평가하였다. 로즈노 연구대상에 포함된 환자 중에서 남자는 19명이었고 여자는 3명이었다 이들의 연령은 25세에서 70세까지 분포하였고, 중앙연령은 56세였다. 종양의 발생 부위에 따라 나누어 보면 비인강암이 13명이었고, 후두암이 6명이었고, 설암, 하인두암, 접형동암이 각각 1예였다. 방사선치료 46 Gy 시점에서 FDG- PET의 섭취가 변화 없는 경우는 1예였고 방사선치료 종료 시점에서 FDG-PET상 완전반응을 보인 경우는 20예였고 1예는 부분반응을 보였다. FDG-PET상 완전반응을 보인 20예 중에서 2예는 국소재발하였고 1예는 국소재발과 경부림프절에 동시에 재발하여 현재까지 3명이 재발하였다 결론 : 방사선치료 46 Gy 시점에서 FDG-PET의 FDG섭취 감소가 현저한 경우는 방사선에 반응을 보이는 것으로 생각되었고 FDG 섭취의 변화가 전혀 없거나 방사선치료 종료 시점에서 FDG-PET 촬영상 완전반응을 보이지 않는 경우 잔존종양의 가능성이 매우 높다고 생각되었다.

• Radiation Oncology Journal
• /
• 제9권1호
• /
• pp.1-6
• /
• 1991

2-ODG가 쥐의 섬유육종(FSall)에 미치는 영향에 대한 연구로 에너지 신진대사는 체내에서의 $^{31}P$-자기공명 분광기를 이용하여 관찰하였고 세포 증식 능력은 유세포 분석기를 사용하여 연구하였다. 성장속도는 10개의 세포를 $C_3Hf/Sed$ 쥐의 발등에 이식한 후 3차원적으로 측정하여 관찰하였다. 2-DDG를 투여한 경우에는 이식후 12일에 복강내로 주사하였다. 이식후 12일의 종양의 평균 크기는 $250mm^3$이었다. Fsall종양의 성장속도는 semilog graph의 기울기와 종양의 doubling time으로 측정하였다. 2-DDG를 투여한 후 성장속도가 감속되었다. 5~12일 사이의 성장속도의 기울기가 0.828, 종양의 Idubling time이 0.84일이고 대조군에서는 13~28일 사이의 기울기가 0.218, doubling time이 3.2일인 반면 2-DOG 투여군에서는 성장속도의 기울기가 0.135이고 doubling time이 5.1일이었다. $^{31}P$-자기공명 분광기를 이용하여 2-DDG의 영향을 분석해 본 결과 2-DDG 투여후 종양증식 속도의 감속과 더불어 phosphornonester (PME)와 inorganic phosphate (Pi)의증가속도가 감소하였다. 이것은 2-DDG투여후 세포의 괴사가 감소하였다는 의미가 있다. 유세포 분석기를 이용하여 종양의 증식 능력을 분석한 결과는 2-DDG 투여후 5-phase와 G2+M phase의 DNA분포가 크게 증가하였다. 이것은 2-DDG투여후 세포가 좀더 방사선에 민감한 cycle로 진행함을 의미하는 것으로 해석할 수 있다. 이에 저자들은 2-DDG가 Fsall 종양세포에 미치는 흥미있는 결과를 토대로 방사선 치료에 미치는 영향과실제 이용 가능성에 대하여 더 연구하고자 한다.